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Abstract Rationale: Phosphodiesterase enzyme type 5
(PDE5) inhibitors and acetylcholinesterase (AChE) in-
hibitors have cognition-enhancing properties. However, it
is not known whether these drug classes affect the same
memory processes. Objective: We investigated the
memory-enhancing effects of the PDE5 inhibitor sildenafil
and AChE inhibitors metrifonate and donepezil in the
object recognition task to find out whether acquisition or
consolidation processes were affected by these drugs.
Methods: The object recognition task measures whether
rats remembered an object they have explored in a
previous learning trial. All drugs were given orally
30 min before or immediately after learning to study
acquisition and consolidation, respectively. Results:
Sildenafil given immediately after the first trial improved
the memory performance after 24 h and resulted in an
inverted U-shaped dose–effect curve with the peak dose at
3 mg/kg. When given before the first trial, sildenafil also
improved the memory performance. However, the dose
needed for the best performance under this condition was
10 mg/kg, suggesting that the dose–effect curve shifted to
the right. This can be explained by the metabolic clearance
of the high dose of sildenafil. Donepezil had no memory
improving effect when given after the first trial. However,
when given before the first trial, a gradually increasing
dose–effect curve was found which had its maximum
effect at the highest dose tested (1 mg/kg). Likewise, only
when metrifonate (30 mg/kg) was given before the first
trial did rats show an improved memory performance.
Conclusion: Our data strongly suggest that PDE5 in-
hibitors improve processes of consolidation of object
information, whereas AChE inhibitors improve processes
of acquisition of object information.
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Introduction
It has been shown that administration of zaprinast,
sildenafil or vardenafil, which are inhibitors of the
phosphodiesterase enzyme type 5 (PDE5) that selectively
breaks down cyclic GMP (cGMP), improves the perfor-
mance of adult rats in an object recognition task
(Prickaerts et al. 1997, 2002b). This suggests that PDE5
inhibitors may have cognition-enhancing properties.
The object recognition task is a one-trial learning task
that measures in a test trial whether rats remember an
object that has been presented in one previous learning
trial. One trial learning task like the object recognition task
allow to investigate different processes of memory,
depending on the time of drug treatment (Izquierdo
1989; Riekkinen et al. 1998; Abel and Lattal 2001;
Prickaerts et al. 2004). Thus, administration of a drug
before the learning trial should have an effect on the
acquisition of information, while administration of a drug
immediately after the learning trial should have an effect
on the consolidation of information. Of note, administra-
tion of a drug before the learning trial may also have an
effect on consolidation and even on retention, depending
on its pharmacokinetic properties. Since all PDE5
inhibitors in previous studies were always administered
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immediately after the learning trial, it was concluded that
processes of early consolidation of object information are
influenced (Prickaerts et al. 1997, 2002b).
Well-known compounds having cognition-enhancing
properties are acetylcholinesterase (AChE) inhibitors such
as metrifonate and donepezil. Cognition-enhancing prop-
erties of both compounds were intensively investigated
and found in various spatial learning tasks with the use of
deficiency models, i.e. animals with lesions in cholinergic
structures or animals treated with anticholinergic drugs
(e.g. Riekkinen et al. 1996; Itoh et al. 1997; Ogura et al.
2000; Chen et al. 2002). Both compounds have also
thoroughly been investigated in one-trial passive avoid-
ance learning tasks in combination with deficiency models
and were found to ameliorate the impaired avoidance
performance (e.g. Riekkinen et al. 1991; Itoh et al. 1997;
Kojima et al. 1997; Bejar et al. 1999; Ogura et al. 2000;
Chopin et al. 2002; Tokita et al. 2002). The passive
avoidance task is a one-trial learning paradigm similar to
the object recognition task. However, in this task subjects
receive an electric foot shock in the acquisition trial and
have to remember this aversive stimulus in the retention
trial.
The effects of metrifonate on one-trial learning in intact
healthy adult rats have been investigated twice in the
passive avoidance task (Schmidt and De Jonge 1991;
Riekkinen et al. 1996) and once in the object recognition
task (Scali et al. 1997a). In these studies, metrifonate was
administered 30 min before the acquisition trial. It is likely
that the compound affected acquisition processes, because
under this condition, the compound had a beneficial effect
on the retention performance, 24 h after the acquisition
trial (Schmidt and De Jonge 1991). To our knowledge, the
pro-cognitive potential of donepezil has never been tested
using a one-trial learning paradigm in healthy adult rats.
The more cognitive processes are improved by a
compound, the more likely it is that it will be useful for
the treatment of memory deficits in patients. In the present
study, we investigated in healthy adult rats the effects of
two classes of drugs with cognition-enhancing potential on
cognitive processes which have not been tested before; we
assessed the effects of PDE5 inhibitors on acquisition, and
of AChE inhibitors on consolidation processes. To
complete the picture, the PDE5 inhibitor sildenafil or the
AChE inhibitor metrifonate or donepezil were adminis-
tered 30 min before or immediately after the learning trial
of the object recognition task. Thus, the effect of each
compound on both acquisition and consolidation of object
information was investigated.
Materials and methods
Animals
All experimental procedures were approved by the local
ethical committee of the Maastricht University for animal
experiments according to governmental guidelines. Male
Wistar rats (Charles River, The Netherlands) were used.
Twelve 5-month-old rats with mean body weights of 428
±7 (SEM) g were used for the metrifonate experiment.
Twenty-four 4-month-old rats weighing on average 341
±3 (SEM) g were used for the sildenafil and donepezil
experiments. The animals were housed individually in
standard type 3 Makrolon cages on sawdust bedding in an
air-conditioned room (about 20°C). They were kept under
a reversed 12/12-h light/dark cycle (lights on from 1800 to
0600 hours) and had free access to food and water.
Treatments
Each compound was freshly dissolved or suspended in its
vehicle on every experimental day. Metrifonate and
donepezil were dissolved in 0.1 M sodium citrate buffer
(pH 5.5) and administered PO in an injection volume of
1 ml/kg. A dose of 30 mg/kg was used for metrifonate and
doses of 0.1, 0.3 and 1 mg/kg were used for donepezil.
Sildenafil, as citrate, was suspended in 1% tylose (methyl-
cellulose) and was given PO in an injection volume of
2 ml/kg. Doses of 1, 3 and 10 mg/kg were used.
Metrifonate, donepezil and sildenafil were administered
both immediately after and 30 min before the first trial in
the object recognition task. Metrifonate, donepezil and
sildenafil were kindly donated by BAYER AG (Wupper-
tal, Germany).
Rats were not housed in the same room as where the
animals were tested. A radio, which was playing softly,
provided background noise in all rooms. All testing was
done between 0900 and 1700 hours. In the following
object recognition experiments each rat served as its own
control. Metrifonate was tested using 12 rats. For the
sildenafil and donepezil study 24 rats were randomly
assigned to two experimental groups of 12 animals each.
One group was used for testing the effects of sildenafil
administration immediately after the first trial in the object
recognition test. This experiment was part of another study
(see Prickaerts et al. 2002b). Subsequently, all 24 rats were
used for the sildenafil treatment 30 min before the first
trial. Thereafter, the rats of the experimental group that
initially had also been treated with sildenafil after the first
trial were now used for testing the effects of donepezil
treatment 30 min before the first trial. At the same time,
the other group was used for the donepezil treatment
immediately after the first trial.
Object recognition task
Metrifonate, donepezil and sildenafil were tested in the
object recognition test which was performed as described
elsewhere (Ennaceur and Delacour 1988). The apparatus
consisted of a circular arena, 83 cm in diameter. Half of
the 40 cm high wall was made of gray polyvinyl chloride,
the other half of transparent polyvinyl chloride. The light
intensity (20 lux) was equal in the different parts of the
apparatus. Two objects were placed in a symmetrical
position about 10 cm away from the gray wall. We used
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four different sets of objects. The different objects were:
(1) a cone consisting of a gray polyvinyl chloride base
(maximal diameter 18 cm) with a collar on top made of
brass (total height 16 cm); (2) a standard 1 l transparent
glass bottle (diameter 10 cm, height 22 cm) filled with
sand; (3) a massive metal cube (10.0×5.0×7.5 cm) with
two holes (diameter 1.9 cm), and (4) a massive aluminum
cube with a tapering top (13.0×8.0×8.0 cm). The objects
could not be displaced by a rat.
In the first week, the animals were handled daily and
were adapted to the procedure in 2 days, i.e. they were
allowed to explore the apparatus (without any objects)
twice for 3 min each day. In the 2 following weeks, the rats
were adapted to the testing and oral administration
procedure by a saline injection (0.4 ml) immediately
after the first trial until they showed a stable discrimination
performance, i.e. a good object discrimination at a 1-h
interval. Subsequently, testing of the drugs began.
A testing session comprised two trials. The duration of
each trial was 3 min. During the first trial (T1), the
apparatus contained two identical objects (samples). A rat
was always placed in the apparatus facing the wall in the
center of the transparent front segment. After the first
exploration period, the rat was put back in its home cage.
Subsequently, after a delay interval, the rat was put back in
the apparatus for the second trial (T2), but now with two
dissimilar objects, a familiar one (the sample) and a new
one. The times spent exploring each object during T1 and
T2 were recorded manually with a personal computer.
Exploration was defined as follows: directing the nose
to the object at a distance of no more than 2 cm and/or
touching the object with the nose. Sitting on the object was
not considered as exploratory behavior. In order to avoid
the presence of olfactory trails, the objects were always
thoroughly cleaned. Moreover, each object was available
in triplicate so none of the two objects from the first trial
had to be used as the familiar object in the second trial. In
addition, all combinations and locations of objects were
used in a balanced manner to reduce potential biases due
to preferences for particular locations or objects.
Since we expected the drug treatments to improve
memory performance, we needed a delay interval at which
no more discrimination between the objects occurs.
Therefore, we selected a delay interval of 24 h, since
there is virtually no discrimination between the two
objects after this interval (Prickaerts et al. 2002a,b). Each
week, two testing sessions were given, one set on Monday
(T1) and Tuesday (T2) and the other set on Thursday (T1)
and Friday (T2). In the sildenafil and donepezil experi-
ments, we tested the different doses of each drug in
random order.
Statistical analysis
The basic measures in the object recognition task were the
times spent by rats exploring an object during T1 and T2
(see Table 1). e1 and e2 are measures of the total
exploration time of both objects during T1 and T2,
respectively. h1 was considered as an index measure of
global habituation of exploratory behavior from T1 to T2.
d2 was considered as an index measure of discrimination
between the new and the familiar objects. In fact, d2 is a
relative measure of discrimination which corrects the
absolute measure of discrimination for exploration activity
(see Table 1). Thus, there should be no differences in d2
indices between experiments with similar treatments at
similar intervals. However, this need not to be the case for
the absolute discrimination measure because of possible
differences in exploration activity. In the present study, the
absolute discrimination measure showed the same results
as the relative discrimination index d2 (data not shown).
In previous studies, we found that a group size of 24 is
sufficient for reliable statistical evaluation (Prickaerts et al.
2002a,b). Thus, the effects of sildenafil administration 30
before T1 were tested in 24 rats in one session only.
Sildenafil administration after T1 and metrifonate and
donepezil administration both before and after T1 were
always tested in 12 rats only, yet in two sessions and the
results of sessions testing the same treatment (dose/
vehicle) condition were averaged.
One-sample t-statistics were performed in order to
assess per treatment condition whether h1 differed from
zero. However, comparison of the value of d2 with the
value zero with no variance may not be the most suitable
way for analyzing recognition (increased chance of
making a type I error). Therefore, we created a virtual
group that shows no discrimination (d2=0) and an SEM
that corresponds to the average SEM (0.065) of seven
independent samples of 24 animals which received vehicle
in previous studies. The number of observations of the
virtual group was always the same as the experimental
group being compared with. The d2 value of zero is based
on the observation that untreated and vehicle-treated
Wistar rats do not discriminate between the objects after
24 h (Prickaerts et al. 2002a,b), and that the average d2
value of the vehicle sessions after a 24-h delay will
approximate zero. On basis of these considerations, we
assume that the comparison by using a t-test of the
individual doses with this virtual group is the most valid
comparison to test the effectiveness of a drug (see also Şık
et al. 2003). Of note, the h1 measure can differ from zero
24 h after a specific vehicle treatment. Consequently, it is
not possible to create the value of h1 of a general virtual
group. Yet it is possible to create the h1 of a virtual group
Table 1 Measures involved in the object recognition test. e1 is the
measure of the time spent in exploring both identical objects (a1 and
a2) in the first trial, and e2 is the measure of the time spent in
exploring both the familiar (a) and new object (b) in the second trial;
h1 is the measure of global habituation from trial 1 to trial 2; d2 is
the relative measure of discrimination between the new and familiar
objects which corrects the absolute discrimination (b−a) for
exploration activity (e2)
Exploration Habituation Discrimination
e1=a1+a2 h1=e1−e2 d2=(b−a)/e2
e2=a+b
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for a specific vehicle treatment if one has enough
observations from previous studies. However, this is not
the case for the present study.
Effects between the different doses of each drug were
analyzed with repeated measures ANOVA over dose. In
the case of a statistically reliable dose effect, comparisons
between means of the different doses were analyzed in
more detail using post hoc Sidak’s t-tests (P< 0.05).
Two rats were removed from the metrifonate experi-
ment: one rat since in one session it showed no exploratory
behavior in T1 (i.e. e1=0), and one rat because of its lack
of exploratory behavior in T2 (i.e. less than 10% of mean
e2). One rat was excluded from the experiment in which
sildenafil was administered immediately after T1 because
of its lack in exploratory behavior in T1 (i.e. less than 10%
of mean e1). In the experiment with donepezil treatment
30 min before T1, one rat was excluded because of its
location preference (i.e. only exploring one and the same
object location in both T1 and T2). Therefore, the final
number of rats per experiment used for analysis were:
metrifonate before and after T1, n=10; sildenafil after T1,
n=11; sildenafil before T1, n=24; donepezil after T1,
n=12; donepezil before T1, n=11.
Results
Metrifonate
Table 2 summarizes the results of treatments with 30 mg/
kg (PO) metrifonate on the activity measures and on the
relative discrimination index d2. Saline treatment after T1,
which is part of the adaptation procedure in the 2 weeks
preceding the drug treatments, showed that these rats did
not discriminate between the objects after a delay interval
of 24 h (index of discrimination d2 was not different from
zero, i.e. the virtual group, after saline treatment; see
Table 2c). Twenty-four hours after treatment with metri-
fonate immediately after T1 the rats did not recognize the
familiar object (see Table 2c).
Subsequently, we also investigated the effects of
metrifonate administration 30 min before T1. Using this
treatment, it was found that the index measure of
habituation of exploratory behavior h1 was different
from zero (see Table 2b). This indicates that the explo-
ration time in T1 was lower than that in T2. d2 was found
to be higher than zero when metrifonate was given 30 min
before T1, thus indicating that 24 h after T1 the
metrifonate-treated rats discriminated between the objects
(see Table 2c).
Sildenafil—treatment after trial 1
Table 3 summarizes results of the sildenafil treatments
immediately after T1 on the activity measures. Figure 1a
illustrates the effects of these sildenafil treatments on the
index of discrimination d2. This experiment was part of
another study (Prickaerts et al. 2002b). No differences
were found between the different doses in the total level of
exploration in T1 [e1; F(3,30)=1.08, n.s.]. Neither were
there differences between the doses in the total exploration
time in T2 [e2; F(3,30)=1.72, n.s.]. At the medium dose
(3 mg/kg), the index measure of habituation of exploratory
behavior h1 differed from zero (see Table 3b). This
indicates that the exploration time was increased from T1
to T2. However, the h1 indices at all treatment conditions
(vehicle/doses) were not different from each other [F(3,30)
=0.67, n.s.].
The index of discrimination d2 showed that 24 h after
T1, the vehicle-treated rats did not discriminate between
the objects (d2 was not different from zero; see Fig. 1a).
After treatment with the medium (3 mg/kg) and high dose
(10 mg/kg) of sildenafil, the rats discriminated between the
objects (d2 values were different from zero; see Fig. 1a).
Comparing between treatment conditions it was found that
the d2 indices differed from each other [F(3,30)=3.88,
P<0.05]. Post hoc analysis showed that the d2 index after
treatment with the medium dose was higher than that after
vehicle and low dose treatment.
Sildenafil—treatment 30 min before trial 1
In this experiment, the low dose of sildenafil (1 mg/kg)
was not tested, since it was assumed to have no effects,
based on the results from the previous sildenafil experi-
ment. The results of the sildenafil treatments 30 min
Table 2 Results of treatment with metrifonate on the activity
measures of the object recognition test. Rats (n=10) received a PO
injection of metrifonate at a dose of 30 mg/kg immediately after or
30 min before the first trial (T1). Saline was given PO after the first
trial only. For each treatment, the averaged data of two sessions are
presented. The delay interval between the first and second trial was
24 h. h1 measures different from zero are depicted with an asterisk
(one-sample t-test, *P<0.05). Likewise, d2 measures different from
the virtual group (mean: 0, SEM: 0.065) are depicted with an
asterisk (t-test, P<0.05)
Saline after T1 Metrifonate after T1 Metrifonate before T1
A. Mean values (±SEM) of total exploration time (s) during the first (e1) and second trial (e2)
e1 11.53 (1.50) 18.55 (1.55) 15.25 (1.35)
e2 14.78 (2.09) 19.22 (2.31) 19.61 (1.21)
B. Mean values (±SEM) of the global index of habituation (h1) from the first to the second trial
h1 −3.25 (1.60) −0.67 (2.26) −4.36 (1.41)*
C. Mean values (±SEM) of the index of discrimination (d2) between the new and familiar objects
d2 −0.11 (0.08) 0.10 (0.08) 0.26 (0.10)*
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before the first trial on the activity measures are
summarized in Table 4. The effects of these sildenafil
treatments on the index of discrimination d2 are shown in
Fig. 1b. The levels of exploration in T1 (e1) and T2 (e2)
were not different between the treatment conditions
(vehicle/doses) (both Fs<2.91, n.s.). The index measures
h1 were not different from zero, indicating that the
exploration time did not change from T1 to T2 after any
treatment (see Table 4b). Between the treatment conditions
there was also no difference in the h1 indices [F(2.46)
=0.45, n.s.].
The index of discrimination d2 showed that 24 h after
T1, the rats did not discriminate between the objects after
vehicle treatment (see Fig. 1b). After treatment with the
medium (3 mg/kg) and high (10 mg/kg) doses of
sildenafil, the rats positively discriminated between the
objects, indicating recognition of the familiar object.
Comparisons between treatment conditions showed a
difference in d2 values [F(2,46)=13.00, P<0.01]. Post-
hoc analysis showed that d2 after treatment with the
medium and high dose was higher than that after vehicle
treatment, while there was no difference in d2 between the
two dose conditions.
Donepezil—treatment after trial 1
The results of the donepezil treatments immediately after
T1 on the activity measures are summarized in Table 5.
Figure 1c illustrates the effects of these donepezil
treatments on the index of discrimination d2. Neither in
T1 nor in T2 was there a difference between the treatment
conditions (vehicle/doses) in the level of exploration (both
Fs<1.76, n.s.). At the highest dose (1 mg/kg) the h1 index
differed from zero (see Table 5b), indicating that the
exploration activity increased from T1 to T2. However, the
Table 4 Results of treatment with sildenafil 30 min before the first
trial on the activity measures of the object recognition test. Rats
(n=24) received a PO injection of vehicle (1% tylose) or sildenafil at
a dose of 3 or 10 mg/kg 30 min before the first trial. The delay
interval between the first and second trial was 24 h. None of the h1
measures was different from zero
Vehicle 3 mg/kg 10 mg/kg
A. Mean values (±SEM) of total exploration time (s) during the first (e1) and second trial (e2)
e1 25.92 (1.97) 24.94 (2.40) 23.15 (1.45)
e2 28.47 (1.94) 25.94 (1.59) 22.95 (1.97)
B. Mean values (±SEM) of the global index of habituation (h1) from the first to the second trial
h1 −2.55 (1.94) −1.00 (2.31) 0.21 (2.01)
Table 3 Results of treatment with sildenafil immediately after the
first trial on the activity measures of the object recognition test. Rats
(n=11) received a PO injection of vehicle (1% tylose) or sildenafil at
a dose of 1, 3 or 10 mg/kg after the first trial. For each treatment, the
averaged data of two sessions are presented. The delay interval
between the first and second trial was 24 h. This experiment was
also part of another study (see Prickaerts et al. 2002b). h1 measures
different from zero are depicted with asterisks (one-sample t-test,
**P<0.01)
Vehicle 1 mg/kg 3 mg/kg 10 mg/kg
A. Mean values (±SEM) of total exploration time (s) during the first (e1) and second trial (e2)
e1 27.20 (2.05) 23.35 (1.94) 24.88 (2.13) 23.98 (1.97)
e2 28.32 (1.89) 26.40 (2.41) 29.68 (1.63) 25.58 (2.02)
B. Mean values (±SEM) of the global index of habituation (h1) from the first to the second trial
h1 −1.12 (2.16) −3.04 (2.34) −4.80 (1.23)** −1.60 (1.48)
Fig. 1 Effects of different doses of a, b sildenafil and c, d donepezil
on the index of discrimination d2 in the object recognition task
(mean values+SEM). Drugs were given both immediately after (a, c)
the first trial or 30 min before (b, d) the first trial (T1). In the vehicle
sessions of the sildenafil and donepezil experiments, rats were
treated (PO) with 1% tylose or 0.1 M sodium citrate buffer (pH 5.5),
respectively. Area between the dotted lines indicates the SEM range
of the virtual group (mean: 0, SEM: 0.065). **Different from virtual
group (t-test, P<0.01)
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h1 indices were not different between treatment conditions
[F(3,33)=1.98, n.s.].
The index of discrimination d2 showed that 24 h after
T1, the rats did not discriminate between the objects, since
d2 was not different from zero after vehicle treatment (see
Fig. 1c). Treatment with different doses of donepezil had
no effect on discrimination performance, as d2 values were
not different from zero (see Fig. 1c). Between the
treatment conditions, vehicle included, there was also no
difference in the d2 indices [F(3.33)=0.31, n.s.].
Donepezil—treatment 30 min before trial 1
The results of the donepezil treatments 30 min before the
first trial on the activity measures are summarized in
Table 6. The effects of these donepezil treatments on the
index of discrimination d2 are illustrated in Fig. 1d. The
levels of exploration in T1 (e1) and T2 (e2) were not
different between the treatment (vehicle/dose) conditions
(both Fs<1.52, n.s.). In the low dose (0.1 mg/kg) condition
the h1 index was different from zero, which indicated that
the exploration time in T1 was lower than that in T2 (see
Table 6b). However, between the treatment conditions
there was no difference in the h1 indices [F(3.30)=2.03, n.
s.].
The index of discrimination d2 showed that 24 h after
T1, the rats did not discriminate between the objects after
vehicle treatment (see Fig. 1d). d2 was higher than zero
only after the high dose treatment indicating discrimina-
tion between the objects at this dose (see Fig. 1d).
Comparisons between treatment conditions showed a
difference in d2 values [F(3.30)=3.44, P<0.05]. Post-hoc
analysis showed that the d2 index of the high dose
treatment was different from the vehicle and low dose
treatments.
Discussion
PDE5 inhibition and object recognition memory
Sildenafil given immediately after the first trial clearly
improved the memory performance in the object recogni-
tion task. This sildenafil treatment resulted in an inverted
U-shaped dose–effect curve with the highest d2 value at a
dose of 3 mg/kg. When given 30 min before the first trial
sildenafil also clearly improved the memory performance.
However, the dose–effect curve was linear in the dose-
range tested, with the best performance at the highest dose
of 10 mg/kg.
Comparison of the two dose–effect curves of the
different sildenafil treatments suggests that administration
of sildenafil before the first trial instead of after the first
trial shifted the dose–effect curve to the right. This is
reflected in the finding that the most effective dose shifted
from 3 mg/kg to 10 mg/kg when changing the adminis-
tration of sildenafil from immediately after to 30 min
before the first trial. This implies that sildenafil has a
positive effect on consolidation of object information since
the high dose of sildenafil given after the first trial had
only an intermediate effect. However, when administered
30 min before the first trial the 10 mg/kg dose resulted in a
maximum effect. It is likely that, as a result of its
metabolic clearance by the liver the high dose (10 mg/kg)
of sildenafil decreased to a similar plasma level as that
produced by the medium (3 mg/kg) dose that was
administered immediately after the first trial. Conse-
quently, the drug appears to maximally improves object
memory performance by influencing consolidation pro-
cesses. This notion is supported by the short elimination
half-life of sildenafil of about 0.4 h in male rats (Walker et
al. 1999). However, 3 mg/kg sildenafil treatment before
the first trial improved object memory, while 1 mg/kg
sildenafil given after the first trial failed to improve
memory. This apparent discrepancy merely indicates that
when giving sildenafil before instead of after the fist trial,
the actual shift of the dose–effect curve to the right was
such that 30 min after administration of 10 mg/kg or 3 mg/
kg, sildenafil levels were somewhat higher than 3 mg/kg
and 1 mg/kg, respectively. Thus, in the latter case it was
high enough to be effective. However, it cannot be
completely ruled out that sildenafil also influences
processes of acquisition.
Sildenafil has been tested in one-trial learning of mice
using the passive avoidance task (Baratti and Boccia
1999). When mice were treated (1–30 mg/kg, IP)
immediately after the learning trial, it was found that
sildenafil improved the memory performance 48 h later.
There was an inverted dose–response U-shaped curve.
However, only a dose of 3 mg/kg sildenafil was effective.
Only this dose of sildenafil was also given 30 min prior to
the first trial and was found to improve the memory
performance to the same magnitude as that produced by
Table 5 Results of treatment with donepezil immediately after the
first trial on the activity measures of the object recognition test. Rats
(n=12) received a PO injection of vehicle (0.1 M sodium citrate
buffer, pH 5.5) or donepezil at a dose of 0.1, 0.3 or 1 mg/kg after the
first trial. For each treatment, the averaged data of two sessions are
presented. The delay interval between the first and second trial was
24 h. h1 measures different from zero are depicted with an asterisk
(one-sample t-test, *P<0.05)
Vehicle 0.1 mg/kg 0.3 mg/kg 1 mg/kg
A. Mean values (±SEM) of total exploration time (s) during the first (e1) and second trial (e2)
e1 22.33 (2.69) 19.97 (2.95) 17.87 (1.20) 17.82 (1.48)
e2 20.12 (1.81) 19.50 (2.06) 19.50 (1.61) 21.26 (1.55)
B. Mean values (±SEM) of the global index of habituation (h1) from the first to the second trial
h1 2.20 (1.90) 0.47 (2.64) −1.64 (1.11) −3.44 (1.38)*
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administration of sildenafil immediately after learning.
Based on our findings, it could be expected that the effect
of this dose of sildenafil should have been weaker.
However, this is not necessarily the case, since the
measurements of the memory improvement in the passive
avoidance task are influenced by many different factors,
such as species-dependent differences in sensitivity to
drug treatment. Nevertheless, evidence is accumulating
that PDE5 inhibition and cGMP are involved in processes
of early consolidation of electric shock and object
information (see also Bernabeu et al. 1996, 1997;
Prickaerts et al. 1997, 2002a,b).
AChE inhibition and object recognition memory
When metrifonate was given 30 min before the first trial, it
improved the performance of the rats. By injecting
donepezil 30 min before the first trial, a gradually
increasing dose–effect curve was found. On the basis of
these data, we argue that the cognition-enhancing effects
of metrifonate and donepezil emerge when the drugs are
active in the learning situation, i.e. these drugs have a
positive effect on acquiring object information. Since
metrifonate and donepezil had no effects when they were
injected immediately after the acquisition trial, they
apparently do not affect the consolidation of object
information. However, it should be noted that the maximal
effect on AChE inhibition by metrifonate and donepezil
can be observed between 30 min and 60 min after drug
administration (Hinz et al. 1996a,b; Van der Staay et al.
1996), which could be a time window that exceeds the
effective consolidation phase. In addition, when metrifo-
nate or donepezil were injected 30 min before the first
trial, they were active not only during the acquisition
phase but also during consolidation. Therefore, although
the present study mainly indicates that the drugs have an
effect on the acquisition of object information, it cannot be
completely ruled out that the drugs have an effect on
consolidation (see also below).
Metrifonate has also been tested in one-trial passive
avoidance learning of intact adult rats. It was found that
metrifonate (30 mg/kg) administered orally 30 min before
the learning trial improved the performance of the rats in
the retention trial (Schmidt and De Jonge 1991). This
“shock” finding corroborates our “object” finding that
metrifonate and donepezil have beneficial effects on the
acquisition of information. One trial learning of adult rats
has also been investigated with the AChE inhibitor tacrine.
In the object recognition task, administration of tacrine
before the learning trial has recently been found to
improve the memory performance (Moser et al. 2002). The
same tacrine treatment was also effective in the passive
avoidance task (Camacho et al. 1996), while administra-
tion immediately after the learning trial had no effect on
the retention performance (Smith et al. 1996). These
results of tacrine are in agreement with our metrifonate
and donepezil data. However, there are also conflicting
data. Administration of metrifonate, tacrine or another
AChE inhibitor, physostigmine, before the learning trial
had no effect on the performance of adult rats in a number
of studies using one-trial learning paradigms (passive
avoidance task: Riekkinen et al. 1991, 1996; Riekkinen
and Riekkinen 1994; object recognition task: Ennaceur
and Meliani 1992; Scali et al. 1997a,b). This lack of an
effect may have been due to a ceiling effect. For instance,
in the object recognition studies a short inter-test interval
of 60 min was used at which the rats still remembered the
familiar object. Thus, the performance of the control
groups was already optimal, so that the metrifonate-treated
and tacrine-treated groups could not outscore this
performance level. In addition, possible adverse choliner-
gic side effects might have influenced the behavioral
performance in the object recognition task (see Yoshida
and Suzuki 1993). However, treatment with physostigmine
after learning even improved the rats’ performance in the
passive avoidance task (e.g. Santucci et al. 1989).
It is difficult to tell whether AChE inhibitors including
metrifonate, donepezil, tacrine and physostigmine have a
positive effect on memory processes of acquisition and/or
consolidation in healthy adult rats. When the same drugs
were tested in the passive avoidance tasks but now using
animal models with experimentally induced deficits, i.e.
animals with lesions in cholinergic structures or animals
treated with for instance scopolamine, then these drugs in
general did mediate cognitive enhancement (e.g. Riekki-
nen et al. 1991, 1996; Yamazaki et al. 1991; Riekkinen
and Riekkinen 1994; Kojima et al. 1997; Ogura et al.
2000; Chopin et al. 2002). However, it should be noted
that in the cholinergic deficiency models, the effects of
metrifonate, donepezil, tacrine and physostigmine on
passive avoidance learning were found not only on
acquisition but also on consolidation (e.g. Ogasawara et
al. 1996; Bejar et al. 1999; Tokita et al. 2002).
Table 6 Results of treatment with donepezil 30 min before the first
trial on the activity measures of the object recognition test. Rats
(n=11) received a PO injection of vehicle (0.1 M sodium citrate
buffer, pH 5.5) or donepezil at a dose of 0.1, 0.3 or 1 mg/kg 30 min
in the first trial. For each treatment the averaged data of two sessions
are presented. The delay interval between the first and second trial
was 24 h. h1 measures different from zero are depicted with an
asterisk (one-sample t-test, *P<0.05)
Vehicle 0.1 mg/kg 0.3 mg/kg 1 mg/kg
A. Mean values (±SEM) of total exploration time (s) during the first (e1) and second trial (e2)
e1 23.44 (1.91) 20.48 (1.79) 23.05 (2.41) 24.44 (2.41)
e2 27.33 (3.06) 27.39 (2.78) 25.79 (3.62) 23.30 (2.70)
B. Mean values (±SEM) of the global index of habituation (h1) from the first to the second trial
h1 −3.89 (2.70) −6.90 (2.91)* −2.74 (2.66) 1.14 (2.11)
387
Metrifonate has also been tested on passive avoidance
learning of healthy adult mice, but appeared to be
ineffective (Ikonen et al. 1999). However, in a cholinergic
(medial septum) lesion model, metrifonate improved the
acquisition of passive avoidance learning (Ikonen et al.
1999). Recently, tacrine has been tested in the object
recognition task with mice, and it was found to improve
consolidation (Chopin et al. 2002). Physostigmine has
only been tested in the passive avoidance task and showed
a positive effect on acquisition (e.g. Zarrindast et al. 1998),
but also on consolidation (e.g. Baratti and Kopf 1996).
Similar results were found in a cholinergic (scopolamine)
deficit model, as acquisition as well as consolidation of
passive avoidance learning were improved by physostig-
mine and donepezil (Suzuki et al. 1995). Taken together,
although a possible effect on consolidation after AChE
treatment cannot be completely ruled out, AChE inhibitors
seem to have a positive effect on the acquisition of object
and electrical shock information in rodents.
Effects of both drug classes on exploratory activity
We observed an incidental increase in exploratory activity
24 h after treatment with the medium dose (3 mg/kg) of
sildenafil and highest dose (1 mg/kg) of donepezil when
administered immediately after the first trial. Close
examination of the changes in activity revealed that they
could not be attributed to sildenafil or donepezil, since the
change in activity after the specific doses of sildenafil or
donepezil was still within the range of the non-significant
changes after the other treatments, vehicle included. For
donepezil an incidental decrease in exploratory activity
was found 30 min after administration of the low dose
(0.1 mg/kg). This was also observed 30 min after the
administration of metrifonate (30 mg/kg). Again, the effect
on exploration of donepezil was still within the range of
the non-significant changes after the other treatments.
Therefore, it can be argued that exploration is not
influenced at both short (30 min) and long (24.5 h)
intervals after treatment with sildenafil, donepezil or
metrifonate.
Possible site and mechanism of action of PDE5
inhibition
The PDE5 inhibitors sildenafil, zaprinast and vardenafil
increase cGMP accumulation in the dorsal hippocampus
as assessed in vitro with radioimmunoassay and immuno-
cytochemistry (De Vente et al. 1996; Van Staveren et al.
2001; Prickaerts et al. 2000b). In addition, it has been
found that injections of 8-bromo-cGMP into the hippo-
campus immediately after the first trial improved the
memory performance in both the object recognition
(Prickaerts et al. 2002a) and passive avoidance task
(Bernabeu et al. 1996). Sildenafil has been demonstrated
to penetrate the brain (FDA 1998). All these findings
support the notion that increased hippocampal cGMP
levels may be responsible for the improved memory
performance in object recognition after treatment with
PDE5 inhibitors.
Several mechanisms of action of cGMP have been
suggested to explain how cGMP exerts its action in
processes of memory. For example, cGMP is thought to
act through regulation of cGMP-gated ion channels,
regulation of cAMP-selective PDEs or activation of
cGMP-dependent protein kinases (Schmidt et al. 1993;
Wei et al. 1998). Despite these findings regarding the
possible mechanisms of cGMP action, it remains unclear
how cGMP produces altered signal transduction, thereby
improving memory performance (for an extensive discus-
sion see Prickaerts et al. 2004). In addition, questions can
be asked about the hippocampus as the site of action of
PDE5 inhibition and thus cGMP, since the role of the
hippocampus in object recognition is a matter of debate
(for review, see Mumby 2001). It has been reported that
object recognition memory does not depend on the
hippocampus but is dependent on the rhinal cortex instead
(Ennaceur and Aggleton 1997; Bussey et al. 1999; Mumby
et al. 2002). Of note, using in situ hybridization, it has
recently been demonstrated that PDE5 mRNA is ex-
pressed in both hippocampus (granule cells, pyramidal cell
and some dispersed cells in the layers) and rhinal cortex
(cells throughout the different layers) (Van Staveren et al.
2003).
The memory improving effects of sildenafil may also,
or alternatively, be related to an increased blood flow and,
consequently, an increased glucose metabolism. PDE5
inhibitors are known to result in vasodilatation, probably
via cGMP (e.g. Dundore et al. 1993). A decreased blood
pressure is also indicative of vasodilatation. It has been
demonstrated that oral administration of 10 mg/kg
sildenafil decreases the systolic arterial blood pressure in
conscious rats (Rehse et al. 1999). This effect lasted for at
least 6 h. Administration of 5 mg/kg sildenafil had no
effect on blood pressure. In a recent study using anesthe-
tized rats, oral administration of 2 mg/kg sildenafil already
increased localized cerebral blood flow during 70 min
after administration of sildenafil (Zhang et al. 2002). In the
present study, the most effective dose of sildenafil was
3 mg/kg PO. Thus, it could be argued that peripheral
administration of sildenafil increased central blood flow.
However, the same doses of sildenafil had different effects
on memory processes of acquisition and consolidation of
object information. This suggests that it is not likely that
the improved object recognition memory after treatment
with sildenafil can be simply explained as a consequence
of changes in blood flow or blood pressure.
Possible site and mechanism of action of AChE
inhibition
The beneficial effects the AChE inhibitors metrifonate and
donezepil on the acquisition of object information in the
adult rat may be mediated via the hippocampus. Assuming
that AChE inhibition is the mechanism of action, it should
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be kept in mind that acetylcholine is also involved in
attentional processes, which may influence/explain the
memory performance (e.g. Blokland 1996). Moreover,
there are arguments in favor of the notion that inhibition of
AChE may not be, or not exclusively be, the mechanism
of action. Although metrifonate and donepezil have long
half-lives, AChE is not chronically inhibited in the present
study, since the highest effective doses tested cause very
weak inhibition of AChE in the rat brain: about 20% after
oral administration of 30 mg/kg metrifonate (Hinz et al.
1996a; Van der Staay et al. 1996) and about 30% after oral
administration of 1 mg/kg donepezil (Van der Staay et al.
1996). In addition, there are indications that local inhibi-
tion of AChE in, for instance, the hippocampus and cortex
may even be less than 10% using such “low” oral doses of
metrifonate and donepezil (Cheng and Tang 1998).
Further, these levels of AChE inhibition are achieved
within 30–60 min in the rat brain and appear to be fully
reversible within 24 h (e.g. Hinz et al. 1996a). These
findings therefore suggest that a mechanism of action
other than AChE inhibition or an additional, not yet
identified one is responsible for the beneficial effect of
donepezil and metrifonate on the object information
processing, as has been suggested earlier for spatial
learning (Van der Staay et al. 1996; Itoh et al. 1997).
Conclusion
Taken together, both PDE5 and AChE inhibitors improved
the performance of rats in the object recognition task. Our
data strongly suggest that PDE5 inhibitors improve
processes of consolidation of object information, whereas
AChE inhibitors improve processes of acquisition,
although consolidation cannot be ruled out completely,
of object information.
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